Key result
Cardiovascular therapeutic innovation is lagging despite high disease burden, requiring global collaboration among academia, industry, and regulators to develop new disruptive treatments.
Key points are not available for this paper at this time.
Design
Editorial
Highlights the need for global collaboration between academia, industry, and regulatory agencies to drive therapeutic innovation in cardiovascular disease.
Cardiovascular disease represents the single largest contributor to morbidity and mortality, yet the flow of therapeutic innovation is lagging. Globally, academia, industry, and regulatory agencies must work together to address this gap, and ensure new disruptive therapeutic modalities to address growing needs of patients and society.
No takes yet. Share an insight, caveat, or question.
Honig et al. (2017) studied this question. Cardiovascular therapeutic innovation is lagging despite high disease burden, requiring global collaboration among academia, industry, and regulators to develop new disruptive treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: